BPC-157 and peptide therapy claims on TikTok, fact-checked

What did @nursey_mercy actually say?

The creator, who identifies as a nurse, is promoting semaglutide (referred to throughout as "some more than," clearly a phonetic rendering of the brand name) for muscle building and recovery. She says her clients love it, her personal results have been visible, and that her recovery time is "so much shorter." She also offers this blunt advice: if a peptide or supplement isn't producing visible results, stop using it.

A few things to flag immediately. Semaglutide is a GLP-1 receptor agonist, not a peptide in the recovery or optimization sense that most people in the peptide-therapy space mean. It's an FDA-approved medication for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Presenting it primarily as a gym performance aid is a notable framing choice, and not a neutral one.

Does the science back this up?

Not for muscle gain. The clinical picture here is actually the opposite of what she's describing. The evidence consistently shows semaglutide causes weight loss that includes significant lean mass loss, not muscle gain.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that participants lost an average of 14.9% of body weight on semaglutide 2.4mg, but lean mass accounted for roughly 39% of total weight lost. That's a meaningful chunk of muscle. A 2023 analysis in Obesity (Bikou et al.) reinforced this, noting that GLP-1 agonists reduce fat-free mass alongside fat mass, particularly without structured resistance training.

Some researchers are exploring whether resistance training can offset this lean mass loss. A small 2024 pilot (Lundgren et al., Journal of Cachexia, Sarcopenia and Muscle) suggested that combining GLP-1 therapy with progressive resistance training preserved more muscle than drug alone. That's a real finding, but it is preliminary and does not support the claim that semaglutide accelerates muscle gains.

What did they get wrong (or right)?

Wrong, and notably so: the framing that semaglutide is a muscle-building "game changer" contradicts the current weight of evidence. If she is lifting consistently and eating adequate protein while on semaglutide, those behaviors deserve the credit for any visible results, not the drug. The medication is more likely working against muscle accrual than supporting it.

The recovery time claim is also unsubstantiated. There is no peer-reviewed evidence that semaglutide shortens exercise recovery. GLP-1 receptors do exist in skeletal muscle and some animal studies (Zhao et al., 2022, Frontiers in Pharmacology) hint at anti-inflammatory effects, but translating that to "recovery time so much shorter" in humans is a leap the data doesn't support yet.

What she did get right: her point that you should feel or see some result from a treatment is reasonable consumer skepticism. It is not a clinical standard, but as a personal heuristic, it is not wrong. Tracking outcomes matters.

What should you actually know?

Semaglutide is a legitimate, well-studied medication with real benefits for people managing obesity or type 2 diabetes. It is not a muscle-building peptide. That distinction matters because people optimizing for body composition face a different risk-benefit calculation than people managing metabolic disease.

If you are already lean and lifting, semaglutide may actively work against your goals by reducing lean mass. If you are overweight and trying to build muscle while losing fat, the picture is more nuanced, and protein intake plus resistance training become even more critical as buffers against muscle loss.

The creator is a nurse promoting a prescription medication on social media for an off-label use (performance and recovery) without mentioning any of the established side effect profile: nausea, vomiting, gastroparesis risk, or the lean mass loss issue. That omission is a problem. Anyone considering semaglutide for fitness goals should have a frank conversation with a licensed provider who can weigh the full picture, not just the highlight reel.